poisar

Stocks · News reference

Intellia Therapeutics Announces Upcoming Clinical Data Presentations for Nexiguran Ziclumeran

Fiscal.ai

Intellia Therapeutics will present new clinical data for nex-z at the American Heart Association (AHA) Scientific Sessions and the International Society of Amyloidosis (ISA) Symposium in November 2026.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncIntellia Therapeutics, Inc.

    Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

    Intellia Therapeutics announced positive clinical data for lonvo-z, its one-time CRISPR gene editing treatment for hereditary angioedema (HAE), presented at ACAAI 2026. Key findings include an 81% reduction in monthly attack rates for patients previously on long-term prophylaxis, with 100% of patients becoming prophylaxis-free. Patient interviews showed 96% described lonvo-z as optimal therapy. The FDA accepted the BLA with Priority Review and a PDUFA target action date of March 10, 2027.